Join our newsletter to stay up to date on cases and settlements.
If you took a drug containing Valsartan and developed Gastric Cancer, Pancreatic Cancer, Bladder Cancer, or Kidney Cancer, you may be entitled to compensation. Learn more about the Valsartan lawsuit today!
Last Update
The Valsartan litigation now includes 1,322 lawsuits, reflecting a steady rise in claims despite the drug being pulled from the market years ago. This trend is common in cases involving latent diseases such as cancer, where symptoms and diagnoses often appear long after exposure. Many plaintiffs are only recently connecting their cancer to years of unknowingly taking contaminated Valsartan. Although the manufacturing issues have been addressed, the litigation continues as the long-term effects of the contamination become more apparent.
Chief Judge Renée Marie Bumb has issued Case Management Order No. 38 to address product identification deficiencies in personal injury claims. If a plaintiff lacks documentary proof linking a manufacturer to their product use, the defendant may issue a deficiency notice via MDL Centrality. Plaintiffs have 30 days to respond or voluntarily dismiss the manufacturer. If unresolved after two case management conferences, defendants may seek an Order to Show Cause, requiring plaintiffs to justify their claims. To avoid dismissal, plaintiffs must provide clear documentation, such as pharmacy receipts or medical records, confirming the manufacturer of the product used.
Plaintiffs’ lawyers in the Valsartan, Losartan, and Irbesartan MDL filed a motion seeking court approval to establish a Qualified Settlement Fund (QSF) for the Hetero settlement. The QSF will manage and distribute settlement funds, ensuring compliance with Section 468B of the Internal Revenue Code. EAG Gulf Coast, LLC will administer the fund, while Western Alliance Bank will act as custodian. The court will oversee the fund, with quarterly statements tracking financial activity. The motion also proposes structured settlements for attorney fees and investments in low-risk instruments. The fund will be closed once all distributions are completed.
The court has officially selected five cases for the second wave of bellwether trials, with the final roster confirmed on December 31, 2024. The designated cases include Dufrene (1:19-cv-15633), Garcia (1:20-cv-07957), Smalls (1:20-cv-08199), Estate of Meeks (1:19-cv-16209), and Suits (20-cv-06547). This selection follows a tentative agreement between both parties earlier in December. Any formal objections must be raised during the scheduled status conference on January 9, 2025, at 11:00 a.m., which will be conducted via Microsoft Teams. These cases will play a pivotal role in shaping the trajectory of the broader litigation.
People across the nation are joining class action lawsuits—and filing individual complaints—after taking valsartan-containing drugs contaminated with potentially carcinogenic (cancer-causing) chemicals.
Valsartan is a generic drug that, for years, was regarded as a safe and effective treatment for high blood pressure, kidney disease, and heart failure. However, a flawed manufacturing process led to hundreds of batches of the medication being contaminated with N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA), probable human carcinogens.
Though the catastrophic error was discovered and the drugs were recalled in 2018, the process causing the contamination had been used since around 2012—meaning countless patients were exposed prior to the recall.
If you or a loved one took a valsartan-containing medication between 2012 and 2018 and developed cancer or another serious illness, you may be eligible to take legal action. Those who took the drug but do not have cancer may still qualify to join a class action lawsuit. Read on to learn more.
Valsartan is an active ingredient used in many prescription drugs. It is classified as an Angiotensin II Receptor Blocker (ARB) and is intended to treat high blood pressure (hypertension) and heart failure. Patients may be prescribed the drug to improve survival following a heart attack, and it may also be used to protect the kidneys in certain patients.
Brand-name drugs containing valsartan include:
Many generic drugs also contain valsartan, including ones that were recalled for NDMA and NDEA contamination:
Though, like any drug, valsartan can cause side effects, the medication itself isn’t known to pose a cancer risk. Instead, the dangers arose from a faulty manufacturing process employed by China-based manufacturer Zhejiang Huahai Pharmaceutical, a company named in the lawsuits.
Around 2012, Zhejiang Huahai Pharmaceutical began producing valsartan using a sodium-azide-based synthesis to cut costs and improve manufacturing efficiency. Disturbingly, this method resulted in chemical reactions that formed probable carcinogens NDMA and NDEA.
In a display of true negligence, Zhejiang Huahai Pharmaceutical did not discover the contamination until mid-2018, when a routine quality test revealed the presence of NDMA (further tests also detected NDEA). They reported their findings to regulatory agencies like the FDA, resulting in the agency’s widespread recalls of valsartan-containing drugs beginning later that year.
Sadly, by that point, numerous contaminated batches of valsartan had already been distributed to and consumed by unknowing patients—likely for years.
Though each contaminated dose contained only small amounts of NDMA or NDEA, the risk to patients is still great since valsartan is frequently used in maintenance drugs intended to be taken routinely (often every day). This means that patients who took contaminated valsartan over an extended period may have been exposed to hazardous levels of carcinogens, increasing their cancer risk—and, in some cases, even causing them to develop cancer.
Eligibility for the valsartan lawsuits depends on several requirements. You may qualify to join if:
Additionally, you must meet the following requirements:
You may also qualify if you've developed cancer(s) such as the following:
The best way to determine your eligibility to bring an individual lawsuit or join a class action is by speaking with a qualified attorney.
Though some generic valsartan-containing drugs were contaminated with NDMA and NDEA and later recalled, not all medications or batches were affected. You can find out if your medication was recalled by utilizing the FDA’s Angiotensin II Receptor Blocker (ARB) recall page. Note that certain other ARB drugs, including losartan and irbesartan, have also been recalled due to contamination.
Here’s how to use the FDA’s recall page:
If you still have questions, your pharmacist should be able to verify if your medication was part of the recall. You can also contact the FDA’s Division of Drug Information (DDI) for verification and more information.
If you did take a recalled ARB medication, you may consider speaking with a qualified attorney, who can inform you of your legal rights. We recommend filling out the form at the top of this page to request a free case evaluation from an attorney in our network.
The valsartan lawsuits make serious allegations against numerous drug manufacturers and distributors, such as:
Allegations made in the lawsuits include that these companies:
Larry Tack is one such patient who filed a valsartan lawsuit. He began taking the drug in April 2015 to help treat his high blood pressure, a choice he and his doctors made based on its purported benefits and seemingly reliable safety profile. Naturally believing he could trust the manufacturer and distributor information, he relied on the medication for more than two years.
Tragically, Tack was diagnosed with esophageal cancer in June 2017. He also learned he had liver cancer that September. Following the FDA’s 2018 recalls, he became convinced that valsartan had caused his cancers.
Despite the illness’s harrowing mental and physical toll, Tack was determined to seek justice, so he sought the help of an experienced legal team, who filed a lawsuit on his and his wife’s behalf. Tack’s case is still pending, and he’s hopeful that a favorable outcome will serve as a warning to large corporations that put profits over safety.
If you were harmed by contaminated valsartan, you may be interested in learning about your legal options. The best way to get started is by speaking with a lawyer who can evaluate your eligibility, determine filing deadlines, and help you gather evidence for your case.
You’ll be interested to know that most attorneys working on these cases require no upfront payment. Instead, you’d pay a portion of your settlement or recovery if your case is successful.
You have a right to answers from the companies that caused you harm, but you don’t have to demand them alone. Attorneys in the OCA network are standing by to fight for the justice you deserve. Complete the form at the top of the page today to be connected with an attorney.
This is an advertisement. OnlyClassActions is not a law firm or referral service, and we do not provide legal advice. OnlyClassActions provides a free service for individuals seeking legal representation, and we do not charge you to be connected with an attorney. We do not recommend or endorse any attorneys that pay to participate. OnlyClassActions utilizes a pool of attorneys in each jurisdiction, and attorneys are selected through a round-robin process without our evaluating your legal situation when selecting which attorney will receive your information. OnlyClassActions makes no representation about the quality of legal services or the qualifications of any attorney participating in our pool. Information you submit will be shared with third-party attorney(s). An attorney-client relationship is not formed when you submit information through the form. Hiring a lawyer is a critical decision and should not be predicated solely on comments, advertisements, or other content found on any website. You are under no obligation to retain a lawyer who contacts you through this service.
Add Comment